Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 9/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384482 | 1.00 | ADRA1A (0.39) | ADRA1AKDM2BKAT2BALDH1A1LMNA | |
| SCHEMBL12396 | 1.00 | ADRA1A (0.39) | ADRA1AKDM2BKAT2BALDH1A1LMNA | |
| SCHEMBL20259924 | 0.87 | KDM2B (0.31) | ADRA1AKDM2BKAT2B | |
| SCHEMBL21161986 | 0.87 | KDM2B (0.31) | ADRA1AKDM2BKAT2B | |
| SCHEMBL25091210 | 0.87 | KDM2B (0.31) | ADRA1AKDM2BKAT2B | |
| SCHEMBL17828049 | 0.86 | KDM2B (0.41) | ADRA1AKDM2BKAT2BALDH1A1LMNA | |
| SCHEMBL12445 | 0.85 | ADRA1A (0.39) | ADRA1AKDM2BKAT2BALDH1A1LMNA | |
| SCHEMBL12449673 | 0.85 | ADRA1A (0.39) | ADRA1AKDM2BKAT2BALDH1A1LMNA | |
| SCHEMBL12718106 | 0.82 | ADRA1A (0.41) | ADRA1AALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL13036987 | 0.82 | ADRA1A (0.41) | ADRA1AALDH1A1LMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022051337-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-03-10 | — | — | WO | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | ADRA1A 3308/4885KDM2B 1388/4885KAT2B 1056/4885 |
| US-10239861-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC11 | ADRA1A 2396/4885KDM2B 2841/4885KAT2B 103/4885 |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC11 | ADRA1A 2396/4885KDM2B 2841/4885KAT2B 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.